Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 1, 2026, the Board of Directors of Tyra Biosciences, Inc. (the Company) designated Julia Rueb, Vice President, Finance of the Company, as the Company's principal accounting officer, succeeding Alan Fuhrman, the Company's Chief Financial Officer, in that role, each effective as of April 1, 2026. Mr. Fuhrman continues to be the Company's principal financial officer.

Ms. Rueb, 40, has served as Vice President, Finance of the Company since January 2024. Previously, Ms. Rueb served as Director and Senior Director of Accounting and Corporate Controller from October 2022 to December 2023. From October 2021 to October 2022, Ms. Rueb served as Associate Director and Director, Technical Accounting at SOAProjects, Inc. From October 2020 to October 2021, Ms. Rueb served as a Manager at van den Boom & Associates LLC, where she provided accounting and finance consulting services to various companies, primarily in the life sciences industry, including the Company. Earlier in her career, Ms. Rueb was employed at Ernst & Young LLP from 2013 to October 2020, most recently serving as an Audit Manager, where she primarily served public life sciences companies. Ms. Rueb holds a Master's degree in Accounting from the University of San Diego and is a Certified Public Accountant. Ms. Rueb has no family relationships with any of the Company's directors or executive officers.